BNET Industries
Last Fiscal Year Sales:$17.5M
- Private
- US
Dow Jones Description
Xcellerex is revolutionizing the way biomolecules are developed, manufactured and commercialized. Xcellerex is built around a unique biomanufacturing platform that features the innovative application of single-use component technology. The Xcellerex platform transforms biomanufacturing economics by enabling: Faster deployment of new manufacturing capacity: 12-18 months vs. 3-5 years. Reduced capital investment: Typical savings of 50% to 70% compared to conventional approaches. Unmatched flexibility: Modular microenvironment approach enables fast, low-cost redeployment for multi-drug production. Xcellerex offers a suite of world-class products and services to support the adoption of its platform. These include the XDR line of single-use bioreactors, PDMaxTM high-throughput process development and optimization services, and proven GMP manufacturing operated by an experienced CMC team. The company also actively seeks creative partnerships to facilitate access to the platform. Further, Xcellerex uses its platform as the foundation for building its own portfolio of proprietary biotherapeutics and vaccines. By leveraging the company's inhouse process development and manufacturing expertise, Xcellerex is able to commercialize biomolecules that may not achieve financial viability using conventional approaches.
Number of Employees 34
Peer Companies
NAICS Code All Other Miscellaneous Manufacturing: 339999
Recent Events
-
Novavax partners with Xcellerex for H1N1 vaccine production
-
Week of Oct. 26, 2009: OXiGENE to Acquire VaxGen; Warner Chilcott Appoints Global R&D President;...
-
Week of Oct. 5, 2009: Merck and CSL Sign Flu Vaccine Pact; Cardinal Health Names...
-
Company and People Notes: Merck and Portola Sign Agreement; Eisai Appoints Senior Vice-Presidents; More ...
-
Francis Collins to head NIH
-
Company and People Notes: Merck and Portola Sign Agreement; Eisai Appoints Senior Vice-Presidents; More ...
News & Analysis
Filter by
xcellerex inc. - All News and Analysis
Xcellerex Announces Appointment of Jonathan Lieber as Chief Financial Officer
- 2009-07-09
MARLBOROUGH, Mass. -- Xcellerex, Inc. announced today the appointment of Jonathan Lieber as Chief Financial Officer. Mr. Lieber joins Xcellerex from Altus Pharmaceuticals, where he was Senior Vice President,...
Xcellerex Announces Sale of FlexFactoryâ?¢ Bioproduction Line to Crucell for Vaccine, Monoclonal Antibody Manufacturing Facility
- 2009-06-17
Bioproduction facility to be completed in First Quarter of 2010, demonstrating game-changing speed of FlexFactory technology MARLBOROUGH, Mass. -- Xcellerex,...
Xcellerex Appoints David J. Williams, Retired Chairman/CEO of Sanofi Pasteur, to its Board of Directors
- 2009-04-01
MARLBOROUGH, Mass. -- Xcellerex, Inc. today announced that it has named David J. Williams, retired Chairman and CEO of Sanofi Pasteur, S.A., the vaccines business of sanofi-aventis Group, to...
Xcellerex, Collaborators Receive $11 Million Phase 2 U.S. Contract to Develop Technology for Accelerated Monoclonal Antibody and Vaccine Manufacturing
- 2009-03-24
MARLBORO, Mass. -- Xcellerex, Inc. announced today that the company, along with three collaborators, has been awarded an $11M Phase 2 contract by the Defense Threat Reduction Agency DTRA...
A consortium that includes deltaDOT, Xcellerex, BioPharm Services and Dowpharma was awarded a $7.9 million
- 2007-10-31
A consortium that includes deltaDOT, Xcellerex, BioPharm Services and Dowpharma was awarded a $7.9 million DARPA grant to develop technology to accelerate the production of vaccines and protein therapeutics.
Xcellerex Secures $31 Million in Series C Financing
- 2007-10-13
Wireless News 10-13-2007 Xcellerex Secures $31 Million in Series C Financing WIRELESS NEWS-October 13, 2007-Xcellerex Secures $31 Million in Series C Financing C2007 10Meters - http://www.10meters.com Xcellerex, Inc. announced that it has raised $31 million in...
Xcellerex Raises $31 Million in Series C Financing
- 2007-10-11
VantagePoint Venture Partners' David E. Thompson to Join Board of Directors MARLBOROUGH, Mass. -- Xcellerex, Inc. announced today that it has raised $31 million in a Series C financing to advance the development and commercialization of its proprietary FlexFactory[TM] manufacturing system and XDR[TM] bioreactors for the production of biomolecules,...
Xcellerex Receives Two Phase I DARPA contracts to Develop Technology To Accelerate Protein and Vaccine Manufacturing
- 2007-07-17
Grants to Xcellerex and Collaborators Total Over $13 Million MARLBORO, Mass. -- Xcellerex, Inc. announced today that the company has received two Phase I contracts awarded by the Defense Advanced Research Projects Agency DARPA for the Accelerated Manufacture of Pharmaceuticals AMP program. The AMP program is a three phase...
Xcellerex Announces Appointment of Joseph Zakrzewski as Chief Executive Officer
- 2007-05-04
CEO transition positions company for next growth stage MARLBOROUGH, Mass. -- Xcellerex, Inc. announced today the appointment of Joseph Zakrzewski as Chief Executive Officer and a member of the company's board of directors. He joins Xcellerex after a nearly 20-year pharmaceutical industry career at Eli Lilly and Company and...
Xcellerex Announces Appointment of John Chickosky as Chief Operating Officer
- 2007-04-09
MARLBOROUGH, Mass. -- Xcellerex, Inc., which provides next generation manufacturing services and systems for biotherapeutics and vaccines based on proprietary, single use, disposable component technology, announced today the appointment of John Chickosky to the newly created position of Chief Operating Officer. Mr. Chickosky joins Xcellerex with more than 20 years...
- 1
- 2
Industry Transcripts by Seeking Alpha
-
Brown Shoe Co. Inc. Q3 2009 Earnings Call Transcript
on Nov 24, 2009about BWS
-
Daktronics Inc. F2Q10 (Qtr End 31/10/09) Earnings Call Transcript
on Nov 24, 2009about DAKT
-
Haynes International Inc. F4Q09 (Qtr End 09/30/09) Earnings Call Transcript
on Nov 24, 2009about HAYN
-
Valspar Corp. F4Q09 (Qtr End 30/10/09) Earnings Call Transcript
on Nov 23, 2009about VAL
-
Donaldson Company Inc. F1Q10 (Qtr End 31/10/09) Earnings Call Transcript
on Nov 19, 2009about DCI
Glass Door
Manufacturing Industry Companies
| Company | Employer Rating |
| Alcoa |  |
| United Technologies | |
| BAE SYSTEMS (United Kingdom) | |
| Textron |  |
| Boeing | |
IndustryTop Rated
